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A B S T R A C T    
Before the introduction of “new drugs,” we designed a trial in which 162 newly diagnosed myeloma 
patients were biologically randomized to receive either an autologous stem cell transplant (auto-SCT) 
followed by a nonmyeloablative allogeneic stem cell transplant (allo-SCT) or a double auto-SCT. Fifty-
eight patients in the allo-SCT arm and 46 in the double auto-SCT arm completed the assigned 
treatment. At a median follow-up of 12.3 years from allo-SCT and 12.1 years from second auto-SCT, 
median overall survival (OS) was 11.4 in the allo-SCT arm and 3.9 years in the auto-SCT -arm (P = 
.007), whereas event-free survival was 3.6 and 1.5 years (P < .001), respectively. A subset of allo-SCT 
patients showed persistent molecular remission. Two-year cumulative incidence of chronic graft-
versus-host disease was 67.2%. At 5 years, 39% of these patients were alive, disease-free, and off 
immunosuppression; 36.6% had relapsed and 12.2% were still on immunosuppres- sion. Thirty-three 
of 58 patients (allo-SCT arm) and 39 of 46 (auto-SCT arm) relapsed at least once and were rescued 
with new drugs. In the allo-SCT arm, 2 patients in biochemical relapse did not reach clinical criteria for 
treatment. Overall 28 (90%) were treated with new drugs and 14 (45%) received donor lymphocyte 
infusions (DLIs). In 28 of 31 patients (90%) DLIs were given with new drugs. Median OS from first 
relapse was 7.5 years in the allo-SCT arm and 2 years in the auto-SCT arm (P = .01). Patients who 
received DLI showed significantly longer OS (hazard ratio, .38; P = .042) as compared with auto-SCT 
patients. This difference was slightly lower when only allo-SCT patients who did not receive DLIs were 
considered (hazard ratio, .56; P = .154). In summary, long-term disease-free survival and survival 
outcomes after treating relapse with new drugs with or without DLIs were better in allo-SCT patients. 
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INTRODUCTION 
Before the introduction of “new drugs,” prospective studies where newly diagnosed myeloma patients 
were “biologically randomized” in the presence or absence of a suitable HLA identical donor were 
conducted [1-6]. Moreover, the concept of temporally splitting myeloablation and immunotherapy was 
explored through a tandem approach with a standard autologous stem cell transplant (auto-SCT) after 
melphalan 200 mg/m2 followed by an allogeneic stem cell transplant (allo-SCT) after 
nonmyeloablative 200 cGy total body irradiation [1,4-8]. The aim was that of reducing tox- icity while 
sparing the graft-versus-myeloma (GVM) effect. Reported clinical outcomes were discordant partly 
due to dif- ferences in study design, patient selection, conditioning regimen, graft-versus-host disease 
(GVHD) prophylaxis, and donor availability. Moreover, prolonged follow-up was needed to detect 
differences in clinical outcomes between patient cohorts [7,8]. Here, we report the impact of new 
drugs on the long-term follow-up of a comparison of allografting with autografting for newly 
diagnosed myeloma designed in the late 1990s. 
 
METHODS 
Study Population and Treatment Assignment 
Study design and clinical outcomes were previously published [1]. Between September 1998 and July 
2004, 162 consecutive patients with newly diagnosed myeloma and at least 1 sibling were enrolled at 
5 centers. Induction therapy included vincristine adriamycin dexamethasone-based regimens and a 
standard autograft. Then, patients received either a nonmyeloablative allograft or a second autograft 
in the presence or absence of a suitable donor. At diagnosis, after HLA typing patients were divided 
into 2 groups: “donor” (n = 80) or “no donor” (n = 82). In the donor group 60 of 80 patients (75%) 
were eligible and gave their written consent to high- dose chemotherapy and tandem auto–allo-SCT 
and 58 of 60 patients (dropout rate, 3%) completed treatment. In the no donor group 59 of 82 patients 
were eligible and assigned to receive high-dose chemotherapy and tandem auto- SCT, and 46 of 59 
(dropout rate, 22%) completed treatment. No maintenance or consolidation was allowed. There were 
no per-protocol indications for treatment at relapse. 
 
Statistical Analysis 
Time-to-event endpoints were calculated from the date of diagnosis for the intention-to-treat analyses 
and from the date of second transplant (allo- SCT or auto-SCT) for the per-protocol indications. Overall 
survival (OS) and event-free survival (EFS) were estimated by the Kaplan-Meier method and 
compared by the Cox proportional hazard model. For analysis of OS after relapse, comparisons 
between groups were also adjusted for age, gender, IgG, Durie-Salmon stage, and for time from SCT to 
relapse. Cumulative in- cidences of nonrelapse mortality, chronic GVHD and discontinuation of 
immunosuppression (IS) were estimated accounting for competing deaths as described by Gooley et al 
[9] and by the Fine and Gray model [10]. 
 
RESULTS 
At the time of this report, median follow-up in the allo- SCT group was 13.1 years (range, 8.3 to 16.3+) 
from diagnosis and 12.3 years (range, 7.7 to 15.3+) from the allo-SCT, whereas median follow-up in 
the auto-SCT group 12.8 years (range, 11.5 to 16.6+) from diagnosis and 12.1 years (range, 10.5 to 
15.4+) from the second auto-SCT. Overall, 29 of 58 patients (50%) in the allo-SCT group and 35 of 46 
patients (76%) in the auto-SCT group died. By intention-to-treat analysis (Figure 1), OS was 8.7 years 
(95% confidence interval [CI], 4.9 to 13.4) in the donor group and 4.2 years (95% CI, 3.3 to 5.8) in the 
no donor group (hazard ratio [HR], .51; 95% CI, .35 to .74; P < .001), whereas EFS was 2.9 years (95% 
CI, 2.3 to 4.3) in the donor group and 2.4 years (95% CI, 2.1 to 2.7) in the no donor group (HR, .62; 
95% CI, .45 to .87; P = .006). 
Patients who completed the assigned treatments (Figure 1) showed a median OS from diagnosis of 
12.1 years (95% CI, 6.6 to not reached) in the allo-SCT group (n = 58) and 5.2 years (95% CI, 3.2 to 8.9) 
in the auto-SCT group (n = 46), a median OS from the second transplant of 11.4 years (95% CI, 5.8 to 
not reached) in the allo-SCT group and 3.9 years (95% CI, 2.1 to 7.6+)  in the auto-SCT group (HR, .51; 
95% CI, .31 to .83;   P = .007), and a median EFS from the second transplant of 3.6 years in the allo-SCT 
group and 1.5 years in the auto-SCT group (HR, .46; 95% CI, .29 to .74; P < .001). By multivariate 
analyses, independent of age, gender, myeloma protein isotype, and Durie-Salmon stage, the presence 
of an HLA-identical sibling was significantly associated with longer OS (HR, .49; 95% CI, 
.34  to  .72;  P < .001)  and  EFS  (HR,  .60;  95%  CI,  .43  to  .85; 
P = .004). Similarly, patients who received allo-SCT showed improved OS (HR, .5; 95% CI, .3 to .84; P = 
.01) and EFS (HR, .41; 95% CI, .25 to .67; P < .001) compared with those who received a second auto-
SCT. 
The major cause of treatment failure and death was disease recurrence in both arms (18/29 [62%] in 
the allo-SCT arm and 33/35 [94%] in the auto-SCT arm). Five-year cumulative in-cidence of 
nonrelapse mortality was 17.2% (95% CI, 7.4 to 27.1) 
after allo-SCT and 4.3% (95% CI, 0 to 10.3) after auto-SCT (P = .030). 
Chronic GVHD developed in 41 patients for a 2-year cumulative incidence of 67.2% (95% CI, 54.9 to 
79.5). Discontinuation of IS after GVHD resolution and achievement of immunotolerance is considered 
a surrogate of good quality of life. Notably, 39% (95% CI, 23.6 to 54.4) of the 41 patients who 
developed chronic GVHD were alive, relapse- free, and eventually off IS at 5 years (Figure 1), whereas 
36.6% had relapsed and 12.2% were still on IS. At the time of follow- up no patient was on IS. 
Overall, 31 of 58 patients (53%) in the allo-SCT group and 39 of 46 patients (85%) in the auto-SCT 
group relapsed. In the allo-SCT group 2 additional patients experienced bio- chemical relapse from 
complete remission without reaching clinical criteria for treatment and were alive at 11 and 13 years, 
respectively, from diagnosis, suggesting prolonged effective GVM; of 31 patients, 14 (45%) received 
donor lymphocyte infusions (DLIs) and 28 (90%) received “new drugs” (Table 1). Moreover, 2 patients 
received a second allo-SCT from the same donor: 1 patient in first relapse died of progression 2 years 
later and the other patient in second relapse is alive 11.5 years from the allo-SCT. Four patients 
developed GVHD after DLI (1 limited, 3 extensive). In the auto-SCT arm, 35 of 39 patients (90%) 
received new drug– based regimens (Table 1). Three of 39 patients (8%) received an allo-SCT from an 
unrelated donor: 2 patients, in first and second relapse, died 6 and 11 years after allo-SCT for 
progression, and 1 patient in third relapse was alive at last follow-up, 3 years after allo-SCT. 
Complete remission was achieved in 16% (5/31) of the allo- SCT patients and in 8% (3/39) of the 
auto-SCT patients at first relapse, in 14% (3/22) and 5% (1/20) at second relapse, and in 6% (1/16) 
and 11% (2/17) at third relapse, respectively (Table 1). After a median follow-up of 9.7 years from 
first relapse, OS was 7.5 years in the allo-SCT arm versus 2.0 years in the auto-SCT (HR, .47; 95% CI, 
.26 to .84; P = .01) (Figure 1). Notably, although the occurrence of chronic GVHD did not impact on 
relapse incidence (HR, 1.01;  95% CI, .46 to 2.2;     P = .989), relapsed patients with previous chronic 
GVHD had a survival advantage (HR, .38; 95% CI, .12 to 1.19; P = .097) com- pared with patients who 
relapsed after allo-SCT without chronic GVHD. Furthermore, after adjusting for age, gender, IgG, Durie-
Salmon stage, and time from SCT to relapse, allo- SCT patients who received DLIs at relapse showed 
significantly longer OS (HR, .38; 95% CI, .15 to .97; P = .042) as compared with auto-SCT patients. 
Interestingly, this difference was slightly lower when allo-SCT patients who did not receive DLI were 
considered (HR, .56; 95% CI, .25 to 1.24; P = .154). 
 DISCUSSION 
After prolonged follow-up, intention-to-treat and per- protocol analyses reinforced the advantage in 
clinical outcomes of allo-SCT observed in the original report [1]. Importantly, a subset of allo-SCT 
patients showed persistent molecular remission [11]. 
Current treatment strategies combining auto-SCT with new drug–based induction and consolidation 
or maintenance allow extended 5-year OS rates up to higher than 60% [12]. Our trial was designed 
almost 20 years ago; therefore, no patients en- rolled could benefit from new drugs upfront. However, 
most relapsed patients were rescued with agents that became avail- able over the following years. The 
efficacy of the combination of new drugs and GVM was highly remarkable as shown by the advantage 
in postrelapse OS observed in allo-SCT patients compared with auto-SCT patients. Importantly, the 
efficacy of DLI with new drugs reinforced the concept that GVM and new drugs are not mutually 
exclusive. Unfortunately, patients were mainly treated outside the context of clinical trials. It is 
therefore not possible to detect a potentially different efficacy of a given class of antimyeloma drugs 
between the 2 patient cohorts. The ”immunoescape” seen at relapse after allo-SCT was likely overcome 
by the antimyeloma effects of new agents that potentiated GVM. In fact, synergism between new 
compounds and allo-SCT was suggested not only in myeloma [6,8] but also in other hematologic 
malignancies [13]. 
The cumulative incidence of chronic GVHD was high in our cohort (67.2%). However, this was not 
completely detrimental because it conferred survival advantage in case of disease relapse and was 
observed, at 5 years, in only 12% of nonrelapsed patients. 
Despite recent improvement in OS after auto-SCT, in a subset of patients OS and EFS are very poor 
even in the era of new drugs [12]. The negative impact of high-risk cytogenetics appeared to be partly 
neutralized by GVM in reports [14,15]. At the time our study was designed, in the late 1990s, 
cytogenetic analysis was not routinely performed. Kröger et al. 
[14] evaluated the impact of molecular remission and high- risk cytogenetics after tandem auto–allo-
SCT. Five-year progression-free survival after allo-SCT was 17% in patients in partial remission, 41% 
in those in complete remission, 57% in molecular remission, and 85% in sustained molecular re- 
mission. There was no statistically significant difference in clinical outcomes between patients with 
del(17p13)/t(4;14) and those without [14]. In another study, Roos-Weil et al. [15] compared patients 
carrying cytogenetic abnormalities in- cluding t(4;14), del(17p), or t(14;16) (n = 53) and those 
without (n = 32). No differences in outcomes were observed. In both studies the authors concluded 
that allo-SCT may be of benefit to high-risk patients. 
In summary, in this follow-up study, long-term disease- free survival and postrelapse survival 
outcomes were significantly better after allo-SCT than after auto-SCT. The role of the combination of 
new drugs and allo-SCT should pro- spectively be explored in high-risk patients, in particular in those 
with early relapse, where prognosis remains poor also in the era of new drugs. 
  
Figure 1. Patient survival. OS (A) and EFS (B) of the “donor” and “no donor” groups from diagnosis by 
intention-to-treat. OS (C) and EFS (D) from second transplant of the “donor” and “no donor” groups by 
per-protocol analysis. (E) OS from first relapse in the allo-SCT arm and auto-SCT arm. (F) Cumulative 
incidence of IS discontinuation (death and relapse were considered as competitive events). 
Table 1 
Salvage Treatments at 
Relapse 
 
 First Relapse     Second 
Relapse 
    Third Relapse     
 Allo-SCT 
Arm 
Response Auto-SCT 
Arm 
Respon
se 
 Allo-SCT Arm Response Auto-SCT 
Arm 
Respon
se 
 Allo-SCT 
Arm 
Response Auto-SCT 
Arm 
Respons
e 
 
 (n = 31)  (n = 39)   (n = 22)  (n = 20)   (n = 16)  (n = 17)   
DLI alone 1 (<1%)  —   —  —   1 (6%) 1 CR — 1 PR  
With chemotherapy 4 (13%) 6 SD 1 (4.5%)  — — — 
With IMiDs 2 (6.5%) 4 PR — 1 SD — — 1 (6%) 
With bortezomib 6 (19%) 3 CR —   
Radiotherapy alone 
 
 
Chemotherapy alone 
4 (13%) 
 
 
2 (6.5%) 
2 SD 
1 PR 
1 CR 
1 SD 
— 
 
 
3 (8%) 
— 
 
 
2 PR 
— 
 
 
2 (9%) 
 
 
1 SD 
— 
 
 
1 (5%) 
 
 
1 SD 
1 (6%) 
 
 
6 (37%) 
1 UK 
 
 
4 SD 
— 
 
 
2 (12%) 
 
 
2 SD 
 
IMiDs 
 
6 (19%) 
1 CR 
3 SD 
 
17 (44%) 
1 PD 
9 SD 
 
7 (32%) 
1 PR 
3 SD 
 
12 (60%) 
 
7 SD 
 
5 (25%) 
2 UK 
3 SD 
 
5 (29%) 
 
2 SD 
 
 
 
Bortezomib 
 
 
 
4 (13%) 
3 PR 
 
 
2 SD 
 
 
 
7 (18%) 
6 PR 
1 CR 
1 PD 
4 SD 
 
 
 
10 (45%) 
2 PR 
1 CR 
1 UK 
3 SD 
 
 
 
3 (15%) 
4 PR 
1 PD 
 
1 SD 
 
 
 
2 (12%) 
2 PR 
 
 
2 PR 
 
 
 
4 (23%) 
3 PR 
 
 
2 SD 
 
 
 
Allograft 
 
 
 
— 
1 PR 
1 UK 
 
 
 
1* (2%) 
2 PR 
1 PD 
 
1 PR 
 
 
 
1† (4.5%) 
4 PR 
2 CR 
1 PD 
1 PR 
 
 
 
1* (5%) 
2 PR 
 
 
1 CR 
 
 
 
1† (6%) 
 
 
 
1 PR 
 
 
 
1† (6%) 
1 CR 
1 PD 
 
1 PR 
Autograft (with new 
drugs) 
 
 
Daratumumab/vorinostat 
— 
 
 
— 
 7‡ (18%) 
 
 
— 
1 SD 
4 PR 
2 CR 
— 
— 
 
 
— 
 3 † (15%) 
 
 
— 
1 SD 
2 PR 
— 
 
 
— 
 2§ (12%) 
 
 
1 (6%)/1 (6%) 
1 SD 
1 UK 
 
CR/PD 
Palliative care 2 (6.5%) — 2 (5%) — 1 (4.5%) — —  —  —  
Unknown —  2 (5%)  —  —  —  —  
 
 
 
 
Dash means none. 
CR indicates complete remission; PR, partial remission; SD, stable disease; IMiDs, immunomodulatory drugs; UK, unknown; PD, progressive disease. 
* Thalidomide given pretransplant. 
† Bortezomib given pretransplant. 
‡ Thalidomide and bortezomib given pretransplant in 1 and 3 patients, respectively. 
§ Bortezomib given pretransplant in 3 patients. 
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